Trial reportBMC gastroenterology2025
The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial.
Trial report in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo investigate the effectiveness of combining ursodeoxycholic acid (UDCA) and vitamin D (VitD) in treating patients with primary biliary cholangitis (PBC) and its impact on hepatic fibrosis.
methodsA prospective analysis was conducted on 60 treatment-naive PBC patients who were admitted to our Infectious Diseases Department and outpatient clinic from May 2021 to December 2022. All patients were taking UDCA capsules orally for one year and were randomly divided into two groups: UDCA + VitD group, which received UDCA combined with VitD (1200 IU/day) treatment, and the UDCA monotherapy group. After one year of treatment, the UDCA monotherapy group was then further stratified into two subgroups using the same method, and treatment was extended for an additional year, to further verify the role of VitD in the treatment of PBC with UDCA. Clinical manifestations, blood tests, and imaging tests were collected before and after treatment. The efficacy was evaluated using the Paris I and Barcelona standards, and the improvement of liver stiffness value was assessed according to the liver stiffness measurement (LSM) using FibroTouch.
resultsAfter one year of treatment, the UDCA + VitD group showed statistically significant decreases in AST, GGT, ALP, Tbil, PT, INR, IgM and LSM levels, and increases in ALB and 25(OH)D levels compared to the UDCA monotherapy group. The 25(OH)D levels had a negative correlation with LSM levels. Additionally, 80.0% of patients in the UDCA + VitD group responded according to the Paris I criteria, while 86.7% responded according to the Barcelona criteria, 50.0% of patients in the UDCA monotherapy group responded according to the Paris I criteria and 63.3% responded according to the Barcelona criteria. The response rate in the UDCA + VitD group was higher than that in the UDCA monotherapy group under both criteria. In the second year of the study after the second randomization, 86.7% of patients responded according to the Paris I criteria in the UDCA + VitD subgroup, while 93.3% responded according to the Barcelona criteria. 53.3% of patients in the UDCA monotherapy subgroup responded according to the Paris I criteria and 66.7% according to the Barcelona criteria. The UDCA + VitD subgroup had a higher Paris I response rate compared with the UDCA monotherapy subgroup.
conclusionsThe combination of UDCA and VitD can increase the drug response rate of UDCA and improve liver function and hepatic fibrosis in PBC patients. VitD may plays an important role in the treatment of PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.